Octagon Capital Advisors LP Reduces Stock Position in Dianthus Therapeutics, Inc. $DNTH

Octagon Capital Advisors LP decreased its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 19.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,946,667 shares of the company’s stock after selling 470,000 shares during the period. Dianthus Therapeutics comprises about 18.1% of Octagon Capital Advisors LP’s holdings, making the stock its largest position. Octagon Capital Advisors LP’s holdings in Dianthus Therapeutics were worth $163,364,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after acquiring an additional 406,254 shares in the last quarter. UBS Group AG grew its stake in shares of Dianthus Therapeutics by 342.6% in the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after acquiring an additional 469,547 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $765,000. BNP Paribas Financial Markets raised its holdings in shares of Dianthus Therapeutics by 1,275.3% in the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock valued at $19,606,000 after purchasing an additional 441,156 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Dianthus Therapeutics by 626.4% during the third quarter. JPMorgan Chase & Co. now owns 68,124 shares of the company’s stock valued at $2,681,000 after purchasing an additional 58,746 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president directly owned 31,249 shares of the company’s stock, valued at $3,157,086.47. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Adam M. Veness sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 87,779 shares of company stock valued at $7,985,235. Company insiders own 3.02% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on DNTH. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wedbush boosted their target price on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Finally, TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Dianthus Therapeutics has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Price Performance

NASDAQ DNTH opened at $103.87 on Monday. The stock has a market capitalization of $5.68 billion, a price-to-earnings ratio of -25.15 and a beta of 1.20. Dianthus Therapeutics, Inc. has a one year low of $18.08 and a one year high of $107.99. The business’s fifty day moving average is $90.72 and its 200-day moving average is $76.22.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. Research analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.